Detalhe da pesquisa
1.
99mTclabeled single-domain antibody for SPECT/CT assessment of HER2 expression in diverse cancer types.
Eur J Nucl Med Mol Imaging;
50(4): 1005-1013, 2023 03.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36482076
2.
De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR-): survival outcomes from a multicentre, open-label, randomised, phase 2 trial.
Lancet Oncol;
23(5): 625-635, 2022 05.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35405088
3.
Impact of RNA Signatures on pCR and Survival after 12-Week Neoadjuvant Pertuzumab plus Trastuzumab with or without Paclitaxel in the WSG-ADAPT HER2+/HR- Trial.
Clin Cancer Res;
29(4): 805-814, 2023 02 16.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36441798
4.
[Prostate and breast cancer: similarities and differences]. / Prostata- und Mammakarzinom: Gemeinsamkeiten und Unterschiede.
Urologie;
61(10): 1068-1075, 2022 Oct.
Artigo
em Alemão
| MEDLINE
| ID: mdl-36038785
5.
Endocrine Therapy Response and 21-Gene Expression Assay for Therapy Guidance in HR+/HER2- Early Breast Cancer.
J Clin Oncol;
40(23): 2557-2567, 2022 08 10.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35404683
6.
Endocrine Therapy in Early Breast Cancer.
Breast Care (Basel);
15(4): 337-346, 2020 Aug.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32982643
7.
The run-in phase of the prospective WSG-ADAPT HR+/HER2- trial demonstrates the feasibility of a study design combining static and dynamic biomarker assessments for individualized therapy in early breast cancer.
Ther Adv Med Oncol;
12: 1758835920973130, 2020.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33281950
8.
Symptomatic bone marrow involvement in breast cancer--clinical presentation, treatment, and prognosis: a single institution review of 22 cases.
Anticancer Res;
31(11): 4025-30, 2011 Nov.
Artigo
em Inglês
| MEDLINE
| ID: mdl-22110237